Loading
Exon 19 deletion and L858R are the two common EGFR mutations, together ~85% of EGFR-mutant lung cancer, and both respond to EGFR pills.
Exon 19 deletions and the L858R point mutation are the two common activating EGFR mutations in non-small-cell lung cancer, and together they account for most EGFR-mutant disease. Both are sensitising: first-line options include osimertinib, amivantamab with lazertinib, and osimertinib combined with chemotherapy, and the older drugs erlotinib and gefitinib were built around the same mutations. Exon 19 deletions tend to respond somewhat better to osimertinib than L858R does. Uncommon mutations such as G719X, L861Q and S768I respond to afatinib, while exon 20 insertions behave differently and need amivantamab or sunvozertinib. The term sits within the receptor tyrosine kinase activation pathway and is linked from the bottleneck on trials not representing the people who get cancer.
In plain words · A growth receptor that is mutated in some lung cancers and overproduced in others; the first great success of targeted pills.
Showing the target this term concerns: EGFR.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares LUX-Lung 3, EGFR L858R, EGFR exon 19 deletion, Gefitinib.
Shares Lazertinib, Amivantamab, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares EGFR L858R, EGFR exon 19 deletion, Erlotinib, Osimertinib.
Shares Lazertinib, Amivantamab, Resectable stage I to III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer.
Shares Lazertinib, Amivantamab, Osimertinib, EGFR.
Shares ARCHER 1050, EGFR L858R, EGFR exon 19 deletion, EGFR.
Shares Gefitinib, Erlotinib, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares ARCHER 1050, Gefitinib, EGFR-mutated non-small-cell lung cancer, EGFR.